The study, published in The Lancet, evaluated the pharmacokinetics, safety and tolerability of two intramuscular formations of lenacapavir in participants ages 18-55 without HIV.
Results showed that a single 5,000-milligram intramuscular dose maintained drug concentrations above levels associated with efficacy in previous phase 3 trials for at least 56 weeks.
Compared to the currently studied biannual subcutaneous version, the annual formulation achieved higher plasma concentrations, suggesting potential for long-lasting HIV prevention.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
